Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at toppennystockmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. TopPennyStockMovers.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent TSVT Stock Price: $2.13
Summary: 2seventy bio Inc. is a cell and gene therapy company. It focuses on the research, development, and commercialization of treatments for cancer. 2seventy bio Inc. is based in Cambridge, Massachusetts.
Samantha Semenkow analyst at Citi reiterates coverage on 2seventy bio (TSVT) stock in the energy sector with a Buy rating and has set TSVT's stock price target at $9.
TipRanks.com reports that 2seventy bio currently has 4 analysts offering 12-month price targets on TSVT and the consensus is a Moderate Buy rating with an average stock price target of $9.75. The most recent TSVT stock price we have is $2.13 and we are not making any TSVT forecasts at this time.
In addition, TradingView issued a sell rating for TSVT over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TSVT. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on TSVT, please click here >>
Terns Pharmaceuticals, TERN
Recent TERN Stock Price: $3.71
Summary: Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY, Calif.
Ritu Baral analyst at TD Cowen reiterates coverage on Terns Pharmaceuticals (TERN) stock in the energy sector with a Buy rating and has not provided TERN's stock price target.
TipRanks.com reports that Terns Pharmaceuticals currently has 4 analysts offering 12-month price targets on TERN and the consensus is a Strong Buy rating with an average stock price target of $15.00. The most recent TERN stock price we have is $3.71 and we are not making any TERN forecasts at this time.
In addition, TradingView issued a sell rating for TERN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on TERN. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on TERN, please click here >>
Gain Therapeutics, GANX
Recent GANX Stock Price: $2.70
Summary: Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain Therapeutics Inc. is based in BETHESDA, Md.
Boobalan Pachaiyappan analyst at H.C. Wainwright reiterates coverage on Gain Therapeutics (GANX) stock in the energy sector with a Buy rating and has set GANX's stock price target at $10.
TipRanks.com reports that Gain Therapeutics currently has 5 analysts offering 12-month price targets on GANX and the consensus is a Strong Buy rating with an average stock price target of $9.20. The most recent GANX stock price we have is $2.70 and we are not making any GANX forecasts at this time.
In addition, TradingView issued a sell rating for GANX over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on GANX. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on GANX, please click here >>
Ambrx Biopharma, AMAM
Recent AMAM Stock Price: $9.83
Summary: Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Joel Beatty analyst at Robert W. Baird reiterates coverage on Ambrx Biopharma (AMAM) stock in the energy sector with a Buy rating and has set AMAM's stock price target at $22.
TipRanks.com reports that Ambrx Biopharma currently has 4 analysts offering 12-month price targets on AMAM and the consensus is a Strong Buy rating with an average stock price target of $26.50. The most recent AMAM stock price we have is $9.83 and we are not making any AMAM forecasts at this time.
In addition, TradingView issued a Neutral rating for AMAM over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AMAM. toppennystockmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AMAM, please click here >>
The editors at toppennystockmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
TopPennyStockMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to TopPennyStockMovers.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================